RJFSA
AGRX

Raymond James Financial Services Advisors’s Agile Therapeutics AGRX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-7
Closed -$26K – 2927
2020
Q1 		$26K Buy
+7
New +$40.2K ﹤0.01% 2357

Other funds holding AGRX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FMBTD
First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Raymond James Financial Services Advisors's AGRX Position: Q2 2020 in Review

Raymond James Financial Services Advisors sold out of Agile Therapeutics (AGRX) in Q2 2020, closing a stake of 7 shares — an estimated $26K sold.

Raymond James Financial Services Advisors first reported a position in AGRX in Q1 2020 and held it in 1 quarter. The position peaked at $26K in Q1 2020. 79 funds tracked by Wall St. Rank hold AGRX as of Q2 2020.

  • Raymond James Financial Services Advisors reported no remaining Agile Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 7 Agile Therapeutics shares in Q2 2020, an estimated $26K.
  • Raymond James Financial Services Advisors first reported a position in Agile Therapeutics in Q1 2020 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Agile Therapeutics position peaked at $26K in Q1 2020.
  • 79 funds tracked by Wall St. Rank held Agile Therapeutics as of Q2 2020.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2020, filed 17 Jul 2020.